...
首页> 外文期刊>Science >Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
【24h】

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

机译:Ultrapotent抗体对不同传播的SARS-COV-2变体

获取原文
获取原文并翻译 | 示例
           

摘要

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617 VOCs. Two antibodies are ultrapotent, with subnanomolar neutralization titers [halfmaximal inhibitory concentration (IC50) 0.3 to 11.1 nanograms per milliliter; IC80 1.5 to 34.5 nanograms per milliliter). We define the structural and functional determinants of binding for all four VOC-targeting antibodies and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting their potential in mitigating resistance development.
机译:对治疗性抗体的高度传播SARS-COV-2变体的出现强调了对持续发现广泛反应性抗体的需求。 我们鉴定了来自三种早期爆发枢纽供体的四个受体结合结构域靶向抗体,其具有效率的中和活性,针对23个变体,包括B.1.1.7,B.1.351,P.1,B.1.429,B.1.526和B. .1.617 VOC。 两种抗体是Ultrapotent,亚胆碱中和滴度[半轴抑制浓度(IC 50)0.3-11.1纳克纳米/毫升; IC80 1.5至34.5纳米每毫升)。 我们为所有四种VOC靶向抗体的结合定义了结构和功能的决定因素,并表明两种抗体的组合降低了逃生突变体的体外产生,表明它们在减轻抗性发育中的潜力。

著录项

  • 来源
    《Science》 |2021年第6556期|759-759|共1页
  • 作者单位

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    Univ N Carolina Sch Med UNC Chapel Hill Sch Publ Hlth Dept Epidemiol Chapel Hill NC 27599 USA|Univ N Carolina Sch Med Dept Microbiol & Immunol Chapel Hill NC 27599 USA;

    Frederick Natl Lab Canc Res Canc Res Technol Program Electron Microscopy Lab Leidos Biomed Res Frederick MD 21702 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    Natl Hlth Lab Serv NHLS Natl Inst Communicable Dis NICD Johannesburg South Africa|Univ Witwatersrand Fac Hlth Sci Sch Pathol SAMRC Antibody Immun Res Unit Johannesburg South Africa;

    Natl Hlth Lab Serv NHLS Natl Inst Communicable Dis NICD Johannesburg South Africa|Univ Witwatersrand Fac Hlth Sci Sch Pathol SAMRC Antibody Immun Res Unit Johannesburg South Africa;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    Frederick Natl Lab Canc Res Canc Res Technol Program Electron Microscopy Lab Leidos Biomed Res Frederick MD 21702 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    Natl Hlth Lab Serv NHLS Natl Inst Communicable Dis NICD Johannesburg South Africa|Univ Witwatersrand Fac Hlth Sci Sch Pathol SAMRC Antibody Immun Res Unit Johannesburg South Africa;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    Univ N Carolina Sch Med UNC Chapel Hill Sch Publ Hlth Dept Epidemiol Chapel Hill NC 27599 USA|Univ N Carolina Sch Med Dept Microbiol & Immunol Chapel Hill NC 27599 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

    NIAID Vaccine Res Ctr NIH Bethesda MD 20892 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号